Nad+ Metabolism Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme and signaling molecule found in all living cells. NAD+ serves as a critical cofactor for sirtuins, poly(ADP-ribose) polymerases (PARPs), CD38/CD157 ectoenzymes, and other metabolic enzymes. Beyond its role in redox biochemistry, NAD+ is a substrate for enzymes that regulate cellular processes fundamental to neurodegeneration: DNA repair, chromatin remodeling, mitochondrial function, calcium signaling, and stress responses. Declining NAD+ levels with age and in neurodegenerative diseases represent a promising therapeutic target.
The kynurenine pathway is the primary de novo biosynthetic route for NAD+:
Tryptophan → N-formylkynurenine → Kynurenine → 3-hydroxyanthranilic acid → Quinolinic acid → QA phosphoribosyltransferase → NAD+
Key enzymes include IDO (Indoleamine 2,3-dioxygenase) and TDO (Tryptophan 2,3-dioxygenase).
Preferential pathway in mammals:
| Enzyme | Function |
|---|---|
| NAMPT | Rate-limiting: nicotinamide → NMN |
| NMNAT | NMN → NAD+ |
| PARP | Consumes NAD+, produces nicotinamide |
| SIRT | Consumes NAD+, produces nicotinamide |
| Precursor | Pathway | Clinical Status |
|---|---|---|
| Nicotinamide riboside (NR) | Salvage | Human trials |
| Nicotinamide mononucleotide (NMN) | Salvage | Human trials |
| Nicotinamide (NAM) | Salvage | Approved supplement |
| Niacin (NA) | Preiss-Handler | Approved |
NAD+ is essential for mitochondrial respiration through its role as an electron carrier. SIRT1, SIRT3, and other NAD+-dependent enzymes regulate mitochondrial biogenesis, dynamics, and quality control through PGC-1α and other targets. Declining NAD+ contributes to mitochondrial dysfunction in AD.
PARP1 consumes NAD+ in DNA repair. Overactivation of PARP1 in AD depletes NAD+ pools, creating a vicious cycle of impaired repair and increased DNA damage.
SIRT1 (nuclear) and SIRT3 (mitochondrial) require NAD+ for activity. SIRT1 regulates tau phosphorylation, amyloid processing, and synaptic plasticity. SIRT3 deacetylates mitochondrial proteins to protect against oxidative stress. Declining NAD+ impairs these protective functions.
NAD+ metabolism regulates inflammatory responses through multiple mechanisms. NAMPT expression is reduced in AD microglia, contributing to inflammatory dysregulation.
PINK1 and Parkin mitophagy require NAD+-dependent signaling. NAD+ repletion enhances mitophagy and protects dopaminergic neurons.
NAD+ levels are reduced in PD brains and models. Restoration of NAD+ protects against MPTP and 6-OHDA toxicity.
NAD+ and sirtuins regulate α-synuclein aggregation and toxicity. SIRT2 inhibition reduces α-synuclein toxicity in models.
Dopaminergic neurons have high energy demands. NAD+ decline impairs ATP production, contributing to neuronal vulnerability.
NAD+ decline is observed in ALS models. NAD+ precursors improve survival in SOD1 mouse models.
NAD+ depletion occurs in HD. SIRT1 activity is impaired, contributing to transcriptional dysregulation. NAD+ repletion improves outcomes in models.
NAD+ metabolism is altered in demyelinating disease. NAD+ precursors may promote remyelination.
| Compound | Trial Phase | Indication | Outcome |
|---|---|---|---|
| NR (Niagen) | Phase I/II | AD | Safety, biomarker changes |
| NMN | Phase I | Aging | Safety, NAD+ increase |
| NRPT | Phase I | Parkinson's | Ongoing |
| Compound | Target | Development |
|---|---|---|
| Resveratrol | SIRT1 | Preclinical/clinical |
| SRT2104 | SIRT1 | Phase I |
| SRT3025 | SIRT1 | Preclinical |
| Drug | Status | Neurodegeneration |
|---|---|---|
| Olaparib | Approved (cancer) | Preclinical |
| Rucaparib | Approved (cancer) | Preclinical |
| PJ34 | Preclinical | Preclinical |
The study of Nad+ Metabolism Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 15 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 38%